ADD

Weak quarter; macro uncertainty weighs on growth

Information Technology > Result Update > July 11, 2025

TCS's Q1FY26 operating performance was weaker than our expectation. Revenue declined 0.6% QoQ (-3.3% CC) to USD7.42bn, below our estimate, impacted by the ramp-down in BSNL deal, delays in decision-making and project commencement with respect to discretionary investments amid elevated macro uncertainty. BSNL deal's ramp-down impacted growth by 2.8%, while international revenue declined 0.5% QoQ in constant currency (CC). EBITM expanded 30bps QoQ to 24.5%. Deal wins remained steady at USD9.4bn (bookto-bill: 1.3x) and a tad above the management's guided comfortable range of USD7-9bn per quarter. The company observed a trend of project deferrals, scope reduction, and decision delays which was intensified to some extent in Q1, resulting in less-than-expected revenue conversion. The management reiterated that international market revenue growth would be better in FY26 vs FY25 and highlighted that if macro improves with no further delays, Q2 could turn out better than Q1. We trim our earnings estimate by ~1.5% for FY27/FY28, factoring in the Q1 performance. We retain ADD with TP of Rs3,500, at 23x Jun-27E EPS.

Results summarv

Revenue declined 0.6% QoQ (down 3.3% QoQ in CC) to USD7.42bn. EBITM expanded 30bps QoQ to 24.5%, a tad above our estimate, supported by lower third-party expenses (+70bps) and currency tailwinds, though partially offset by lower utilization. Cost of equipment and software licenses decreased ~USD232mn QoQ which partly indicates BSNL deal's ramp-down. Among geographies, North America, the UK, Continental Europe, and APAC saw increases of 0.4%, 6.5%, 4.3%, and 3.1% QoQ, respectively (in USD terms), while India saw a decline of 31.4% QoQ. Revenue decline in India is largely owing to the ramp-down in the BSNL deal. Headcount grew 0.8% QoQ to 613,069. Attrition inched up to 13.8%, from 13.2% in Q4FY25. TCS has announced an interim dividend of Rs11/share. What we like: Strong deal intake, steady cash conversion. What we did not like: Revenue miss, weak revenue conversion.


Earnings call KTAs

1) The deal pipeline continues to remain healthy and well distributed across verticals and geographies. 2) BFS clients are cautious with investments due to macro uncertainty; US insurance continues to remain soft, while Europe is doing well. Discretionary spends remain under pressure. 3) MedTech faces regulatory scrutiny, shifting demand patterns, cost pressures, and regional consolidation. 4) Consumer remains the most impacted vertical, driven by funding delays, project postponements, and delayed milestone completions. 5) Enterprises in CMT are re-evaluating their priorities with key focus on AI, automation, cost optimization, and vendor consolidation 6) Manufacturing remains subdued due to challenges and reduced spending in Auto. Clients are focused on lowering tech debt and preparing infrastructure for future demand. 7) Spending and capital investment in ERU is down amid policy changes and geopolitical tensions... (cont)...

TCS: Financial Snapshot (Consolidated)								
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E			
Revenue	2,408,930	2,553,240	2,616,336	2,799,611	2,984,590			
EBITDA	633,370	674,070	697,910	758,674	809,066			
Adj. PAT	459,080	485,530	506,527	543,479	578,630			
Adj. EPS (Rs)	126.9	134.2	140.0	150.2	159.9			
EBITDA margin (%)	26.3	26.4	26.7	27.1	27.1			
EBITDA growth (%)	6.9	6.4	3.5	8.7	6.6			
Adj. EPS growth (%)	10.2	5.8	4.3	7.3	6.5			
RoE (%)	49.6	51.2	51.0	52.3	53.1			
RoIC (%)	100.3	100.3	98.7	102.5	102.4			
P/E (x)	26.7	25.2	24.2	22.5	21.1			
EV/EBITDA (x)	18.6	17.5	16.9	15.5	14.5			
P/B (x)	13.2	12.6	12.0	11.5	11.0			
FCFF yield (%)	3.8	4.0	4.2	4.3	4.6			

Source: Company, Emkay Research





Jan-25

Apr-25

Rel to Nifty (RHS)



52-weel	k High (Rs)	4,520
52-weel	k Low (Rs)	3,056
Shares	outstanding (mn)	3,618.1
Market-	cap (Rs bn)	12,236
Market-	cap (USD mn)	142,873
Net-deb	t, FY26E (Rs mn)	(511,469.5)
ADTV-3	M (mn shares)	3
ADTV-3	M (Rs mn)	8,862.0
ADTV-3	M (USD mn)	103.5
Free floa	at (%)	28.2
Nifty-50)	25,355.3
INR/US	D	85.6

Shareholding, Mar-25

Jul-24

Oct-24

Dipeshkumar Mehta

+91-22-66121253

+91-22-66121255 Shivang Bagla

+91-22-66242491

Jimit Gandhi

dipeshkumar.mehta@emkayglobal.com

jimit.gandhi@emkayglobal.com

shivang.bagla@emkayglobal.com

TCS IN Equity (LHS)

Sharenolanig, Har 25	
Promoters (%)	71.8
FPIs/MFs (%)	12.0/11.6

Price Perform	nance		
(%)	1M	ЗМ	12M
Absolute	(2.3)	4.2	(12.1)





Jun-26

CMP (Rs): 3,382 | TP (Rs): 3,500

Target Price - 12M

Change in TP (%)

... (cont)... 8) Across industries, clients are increasingly shifting their focus from use casebased approach to RoI-led scaling of AI. 9) Deal wins were steady at USD9.4bn (book-to-bill ~1.3x) in Q1 (excluding the BSNL APO). 10) Enterprises are moving beyond pilots to production-grade GenAI rollouts, focusing on AI-led business transformation, AI-enabled SDLC, and data platform modernization. 11) TCS is expanding its AI platform (TCS WisdomNext) with agentic AI capabilities and strengthening partnerships with hyperscalers and native AI and data companies. It is investing across the AI ecosystem, including infrastructure, data platform solutions, AI agents, and business applications. 12) Customer spend is clustering around three big themes (a) AI-led business transformation, (b) AIenabled SDLC/IT operations, and (c) data platform modernization that supports agentic AI. 13) TCS has over 114,000 people with higher order AI skills. 14) The company is recalibrating its hiring based on the demand outlook and will decide on wage hike for FY26 based on the macro environment.

Exhibit 1: Quarterly Snapshot

Particular (Rs mn)	Q1 FY26	Q4 FY25	QoQ (%)	Q1 FY25	YoY (%)
Net sales (USD mn)	7,421	7,465	-0.6	7,505	-1.1
Net sales	634,370	644,790	-1.6	626,130	1.3
Operating expenses	465,620	474,990		459,510	
EBITDA	168,750	169,800	-0.6	166,620	1.3
Margins (%)	26.6	26.3	30.0	26.6	-
Depreciation	13,610	13,790		12,200	
EBIT	155,140	156,010	-0.6	154,420	0.5
Margins (%)	24.5	24.2	30.0	24.7	(20.0)
Other income	14,650	8,010		7,890	
Pre-tax profit	169,790	164,020	3.5	162,310	4.6
Tax provided	41,600	41,090		41,260	
Profit after tax	128,190	122,930		121,050	5.9
Emkay - Net profit	127,600	122,240	4.4	120,400	6.0
EPS (Rs)	35.3	33.8	4.4	33.3	6.0

Source: Company, Emkay Research

Exhibit 2: Actuals vs Estimates

(De ma)	Actual	Est	timate	Variation		
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Revenue (USD mn)	7,421	7,577	7,504	-2.1%	-1.1%	Revenues were weaker than estimates.
Sales	634,370	648,589	642,230	-2.2%	-1.2%	
EBIT	155,140	157,607	156,062	-1.6%	-0.6%	EBITM came a tad above our expectation.
EBIT margin	24.5%	24.3%	24.3%	20 bps	20 bps	
PAT	127,600	122,500	122,024	4.2%	4.6%	Reported profit beat expectations due to higher other income (includes one-off interest on tax refunds of ~Rs6bn).

Source: Company, Emkay Research

Exhibit 3: Changes in estimates

		FY26E		FY27E			FY28E		
(Rs mn)	Old	New	Change	Old	New	Change	Old	New	Change
Revenue	30,803	30,334	-1.5%	32,498	31,996	-1.5%	34,456	33,916	-1.6%
YoY growth (%)	2.1	0.5		5.5	5.5		6.0	6.0	
Revenue	2,657,612	2,616,336	-1.6%	2,843,555	2,799,611	-1.5%	3,032,163	2,984,590	-1.6%
EBIT	649,805	642,678	-1.1%	710,867	699,882	-1.5%	758,287	746,389	-1.6%
EBIT margins (%)	24.5	24.6		25.0	25.0		25.0	25.0	
Net profit	504,606	506,527	0.4%	550,957	543,479	-1.4%	587,181	578,630	-1.5%
EPS (Rs)	139.5	140.0	0.4%	152.3	150.2	-1.4%	162.3	159.9	-1.5%

Source: Company, Emkay Research

his report is intended for Team White Marque Solutions (team.emkav@whitemarquesolutions.com) use and downloade





Source: Company, Emkay Research

his report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloaded

TCS: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	2,408,930	2,553,240	2,616,336	2,799,611	2,984,590
Revenue growth (%)	6.8	6.0	2.5	7.0	6.6
EBITDA	633,370	674,070	697,910	758,674	809,066
EBITDA growth (%)	6.9	6.4	3.5	8.7	6.6
Depreciation & Amortization	49,840	52,420	55,231	58,792	62,676
EBIT	583,530	621,650	642,678	699,882	746,389
EBIT growth (%)	7.6	6.5	3.4	8.9	6.6
Other operating income	-	-	-	-	-
Other income	44,220	39,620	46,284	41,278	42,318
Financial expense	7,780	7,960	7,950	8,000	8,000
PBT	619,970	653,310	681,012	733,160	780,708
Extraordinary items	0	0	0	0	0
Taxes	158,980	165,340	171,962	186,956	199,080
Minority interest	(1,910)	(2,440)	(2,523)	(2,725)	(2,998)
Income from JV/Associates	0	0	0	0	0
Reported PAT	459,080	485,530	506,527	543,479	578,630
PAT growth (%)	8.9	5.8	4.3	7.3	6.5
Adjusted PAT	459,080	485,530	506,527	543,479	578,630
Diluted EPS (Rs)	126.9	134.2	140.0	150.2	159.9
Diluted EPS growth (%)	10.2	5.8	4.3	7.3	6.5
DPS (Rs)	73.0	126.0	127.0	137.0	146.0
Dividend payout (%)	57.5	93.9	90.7	91.2	91.3
EBITDA margin (%)	26.3	26.4	26.7	27.1	27.1
EBIT margin (%)	24.2	24.3	24.6	25.0	25.0
Effective tax rate (%)	25.6	25.3	25.3	25.5	25.5
NOPLAT (pre-IndAS)	433,894	464,323	480,396	521,412	556,060
Shares outstanding (mn)	3,618	3,618	3,618	3,618	3,618

Balance Sheet					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	3,620	3,620	3,620	3,620	3,620
Reserves & Surplus	922,500	965,200	1,012,230	1,060,032	1,110,420
Net worth	926,120	968,820	1,015,850	1,063,652	1,114,040
Minority interests	8,300	10,150	12,673	15,398	18,396
Non-current liab. & prov.	(23,920)	(25,600)	(26,600)	(27,600)	(28,600)
Total debt	0	0	0	0	0
Total liabilities & equity	990,710	1,047,290	1,095,463	1,144,990	1,197,376
Net tangible fixed assets	112,240	129,320	130,320	131,320	132,320
Net intangible assets	5,100	9,400	9,400	9,400	9,400
Net ROU assets	78,860	92,750	92,750	92,750	92,750
Capital WIP	-	-	-	-	-
Goodwill	-	-	-	-	-
Investments [JV/Associates]	-	-	-	-	-
Cash & equivalents	468,250	472,300	511,469	526,527	544,137
Current assets (ex-cash)	747,690	838,140	857,245	915,478	974,225
Current Liab. & Prov.	461,320	534,860	545,961	570,725	595,696
NWC (ex-cash)	286,370	303,280	311,284	344,753	378,529
Total assets	990,710	1,047,290	1,095,463	1,144,990	1,197,376
Net debt	(468,250)	(472,300)	(511,469)	(526,527)	(544,137)
Capital employed	990,710	1,047,290	1,095,463	1,144,990	1,197,376
Invested capital	443,600	482,240	491,244	525,713	560,489
BVPS (Rs)	256.0	267.8	280.8	294.0	307.9
Net Debt/Equity (x)	(0.5)	(0.5)	(0.5)	(0.5)	(0.5)
Net Debt/EBITDA (x)	(0.7)	(0.7)	(0.7)	(0.7)	(0.7)
Interest coverage (x)	80.7	83.1	86.7	92.6	98.6
RoCE (%)	67.2	69.1	68.6	70.3	71.3

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	585,880	643,830	506,527	543,479	578,630
Others (non-cash items)	209,160	218,610	57,754	61,517	65,674
Taxes paid	(124,890)	(155,860)	0	0	0
Change in NWC	(75,940)	(36,460)	(9,004)	(34,469)	(34,776)
Operating cash flow	469,320	514,260	555,278	570,527	609,528
Capital expenditure	(26,470)	(39,090)	(56,231)	(59,792)	(63,676)
Acquisition of business	0	(10,630)	0	0	0
Interest & dividend income	38,220	33,430	39,464	34,078	35,118
Investing cash flow	27,340	(46,130)	(99,101)	(59,792)	(63,676)
Equity raised/(repaid)	(210,050)	0	0	0	0
Debt raised/(repaid)	0	0	0	0	0
Payment of lease liabilities	(16,140)	(16,640)	(380)	0	0
Interest paid	-	-	-	-	-
Dividend paid (incl tax)	(252,180)	(449,620)	(459,497)	(495,678)	(528,241)
Others	0	280	0	0	0
Financing cash flow	(478,370)	(465,980)	(459,877)	(495,678)	(528,241)
Net chg in Cash	18,290	2,150	(3,701)	15,057	17,611
OCF	469,320	514,260	555,278	570,527	609,528
Adj. OCF (w/o NWC chg.)	545,260	550,720	564,282	604,996	644,304
FCFF	442,850	475,170	499,047	510,735	545,851
FCFE	473,290	500,640	530,560	536,813	572,969
OCF/EBITDA (%)	74.1	76.3	79.6	75.2	75.3
FCFE/PAT (%)	103.1	103.1	104.7	98.8	99.0
FCFF/NOPLAT (%)	102.1	102.3	103.9	98.0	98.2

Source: Company, Emkay Research

Source: Company, Emkay Research

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	26.7	25.2	24.2	22.5	21.1
EV/CE(x)	12.6	12.0	11.4	10.9	10.4
P/B (x)	13.2	12.6	12.0	11.5	11.0
EV/Sales (x)	4.9	4.6	4.5	4.2	3.9
EV/EBITDA (x)	18.6	17.5	16.9	15.5	14.5
EV/EBIT(x)	20.2	18.9	18.3	16.8	15.8
EV/IC (x)	26.5	24.4	24.0	22.4	21.0
FCFF yield (%)	3.8	4.0	4.2	4.3	4.6
FCFE yield (%)	3.9	4.1	4.3	4.4	4.7
Dividend yield (%)	2.2	3.7	3.8	4.1	4.3
DuPont-RoE split					
Net profit margin (%)	19.1	19.0	19.4	19.4	19.4
Total asset turnover (x)	2.6	2.7	2.7	2.7	2.8
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0
RoE (%)	49.6	51.2	51.0	52.3	53.1
DuPont-RoIC					
NOPLAT margin (%)	18.0	18.2	18.4	18.6	18.6
IC turnover (x)	5.6	5.5	5.4	5.5	5.5
RoIC (%)	100.3	100.3	98.7	102.5	102.4
Operating metrics					
Core NWC days	43.4	43.4	43.4	44.9	46.3
Total NWC days	43.4	43.4	43.4	44.9	46.3
Fixed asset turnover	15.0	15.2	14.6	15.5	16.4
Opex-to-revenue (%)	73.7	73.6	73.3	72.9	72.9

Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team.emkay@whitemarguesolutions.com) use and downloade

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
01-Jul-25	3,430	3,500	Add	Dipeshkumar Mehta
11-Apr-25	3,232	3,500	Add	Dipeshkumar Mehta
31-Mar-25	3,606	3,900	Add	Dipeshkumar Mehta
10-Jan-25	4,266	4,500	Add	Dipeshkumar Mehta
01-Jan-25	4,112	4,500	Add	Dipeshkumar Mehta
11-Oct-24	4,149	4,500	Reduce	Dipeshkumar Mehta
01-Oct-24	4,288	4,500	Reduce	Dipeshkumar Mehta
01-Jul-24	3,978	3,950	Reduce	Dipeshkumar Mehta
01-Jul-24	3,978	3,950	Reduce	Dipeshkumar Mehta
09-Jun-24	3,894	3,950	Reduce	Dipeshkumar Mehta
03-Jun-24	3,703	3,950	Reduce	Dipeshkumar Mehta
27-May-24	3,847	3,950	Reduce	Dipeshkumar Mehta
13-Apr-24	4,001	3,950	Reduce	Dipeshkumar Mehta
31-Mar-24	3,876	3,900	Reduce	Dipeshkumar Mehta
01-Mar-24	4,094	3,900	Reduce	Dipeshkumar Mehta
12-Jan-24	3,883	3,900	Reduce	Dipeshkumar Mehta
31-Dec-23	3,793	3,900	Reduce	Dipeshkumar Mehta
30-Nov-23	3,488	3,550	Reduce	Dipeshkumar Mehta
12-Oct-23	3,543	3,550	Hold	Dipeshkumar Mehta
02-Oct-23	3,529	3,550	Hold	Dipeshkumar Mehta

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Source: Company, Emkay Research

I his report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloade

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Margue Solutions (team.emkav@whitemarguesolutions.com) use and downloade

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 11, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 11, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 11, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.

This report is intended for Team White Margue Solutions (team.emkay@whitemarguesolutions.com) use and downloaded